RT Book, Section
A1 Balagtas, Jay Michael S.
A1 Lacayo, Norman
A2 Stevenson, David K.
A2 Cohen, Ronald S.
A2 Sunshine, Philip
SR Print(0)
ID 1109798755
T1 Transient Myeloproliferative Disorder
T2 Neonatology: Clinical Practice and Procedures
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071763769
LK accesspediatrics.mhmedical.com/content.aspx?aid=1109798755
RD 2024/04/25
AB Transient  myeloproliferative  disorder  (TMD)  is  a  unique  clonal  proliferation  of  megakaryocytic  precursors  that  is  clinically  indistinguishable  from  congenital  leukemia  and  is  seen  almost  exclusively  in  neonates  with  trisomy  21  (Down  syndrome).1  TMD  is  typically  characterized  by  the  presence  of  leukocytosis  and  circulating  blast  cells  in  the  blood  of  an  otherwise  healthy-appearing  newborn.  These  blast  cells  will  generally  resolve  spontaneously  by  3–6  months  of  age  without  any  specific  interventions.2  However,  approximately  20%  of  patients  will  present  with  severe  hydrops,  organomegaly,  hepatic  fibrosis,  and  other  life-threatening  complications,  with  an  associated  mortality  rate  approaching  45%  at  3  years.3